Home
Series of Journals
Literature
Latest literature
Popular literature
About us
Intro
Organizational structure
Job Responsibilities
Copyright
Contact us
The title
The title
The keywords
The author
Wuhan University
Zhongnan Hospital of Wuhan University
Center for Evidence-Based and Translational Medicine of Wuhan University
Home
Results
The title
The title
The keywords
The author
A total of
15
result was found. Results that relate to
Economics
Conflict of interest and economic evidence in Chinese clinical practice guidelines published in 2021: a survey
Published on
New Medicine
2023,33(1):8-49.
16132 times
3528 times
Yan-Bo WANG
Ming-Juan ZHAO
Qiang WANG
Hui-Zhong XU
Hua TAO
Jia-Ping GUO
Xiu-Sen HUANG
Xue-Qun REN
Xian-TAO ZENG
Clinical practice guidelines
Conflict of interest
Economics
Financial resources
Evidence-based medicine
Details
Pharmacoeconomic evaluation of Huangkui capsule versus losartan potassium tablets in the treatment of IgA nephropathy
Published on
Chinese Journal of Pharmacoepidemiology
2023,32(1):02-09.
13111 times
4902 times
Liang-Wen GOU
Zhao-Ting GUO
Qiong LUO
Nan YANG
Ming HU
Huangkui capsule
Losartan potassium tablets
Chronic kidney disease
Pharmaco
economics
Cost-utility analysis
Details
Bibliometric analysis of pharmacoeconomics evaluation research in China: based on the Web of Science database
Published on
Journal of Mathematical Medicine
2023,36(3):185-193.
8693 times
2399 times
Yu-Liang GUI
Shi-Qiang XIANG
Pharmaco
economics
evaluation
CiteSpace
Bibliometrics
Visual analysis
Details
Cost-utility analysis of azacitidine versus decitabine in the treatment of myelodysplastic syndrome
Published on
Chinese Journal of Pharmacoepidemiology
2023,32(12):1371-1379.
11821 times
2707 times
La-Ji DANZENG
Yong-Gong YANG
Si-Liang WANG
Meng-Ying LIU
Azacitidine
Decitabine
Myelodysplastic syndrome
Markov model
Cost-utility analysis
Pharmaco
economics
Details
Pharmacoeconomic study of Bailing capsules plus conventional therapy in treating diabetic kidney disease
Published on
Chinese Journal of Pharmacoepidemiology
2024,33(3):277-290.
11595 times
2745 times
HE Yumei
LI Wei
ZHU He
HAN Sheng
Bailing capsules
Diabetic kidney disease
Meta-analysis
Cost- effectiveness analysis
Pharmaco
economics
Details
Partitioned survival model of pharmacoeconomics evaluation of oncology therapy in R language
Published on
Journal of Mathematical Medicine
2024,37(4):240-251.
17964 times
3146 times
LIU Jiayi
LI Wei
R language
Pharmaco
economics
evaluation
Health economic evaluation
Partitioned survival model
Oncology treating drugs
Details
Pharmacoeconomic evaluation of glucagon-like peptide-1 receptor agonist combined with metformin in the treatment of type 2 diabetes mellitus
Published on
Chinese Journal of Pharmacoepidemiology
2024,33(4):388-401.
13483 times
3328 times
YU Tian
LIU Shaohua
WEI Anhua
GUO Jieru
ZHANG Chengliang
LIU Dong
LIU Zhelong
Glucagon-like peptide-1 receptor agonist
Metformin
Type 2 diabetes mellitus
Cost-utility
Markov model
Pharmaco
economics
Details
Systematic review of studies on the economics of different pharmacy services provided by clinical pharmacists
Published on
Frontiers in Pharmaceutical Sciences
2024,27(4):674-683.
11510 times
2442 times
Adili·TUERSUN
CHENG Gang
Clinical pharmacists
Pharmacy services
Economics
studies
Systematic review
Details
Cost-utiliy comparison of ranibizumab or aflibercept in the treatment of diabetic macular edema based on a Markov model
Published on
Frontiers in Pharmaceutical Sciences
2024,27(7):1155-1161.
11856 times
2123 times
ZHU Yanxia
ZHOU Ruting
SHI Tianyan
Diabetic macular edema
Aflibercept
Ranibizumab
Pharmaco
economics
Details
Pharmacoeconomic evaluation of third-line treatment of advanced non-small cell lung cancer with anlotinib
Published on
Frontiers in Pharmaceutical Sciences
2024,28(4):639-647.
14320 times
1921 times
YUAN Wenjie
KANG Shuo
WANG Xiaohui
GONG Yuan
PAN Zhenhua
Anlotinib
Pharmaco
economics
Non-small cell lung cancer
Cost-utility analysis
Details
Cost-effectiveness analysis of low-dose steriod combined with tacrolimus or cyclophosphamide in the treatment of adult idiopathic membranous nephropathy
Published on
Chinese Journal of Pharmacoepidemiology
2025,34(2):175-181.
13992 times
2389 times
GUO Shanshan
GUO Li
LI Jiandong
ZHENG Xijie
CHEN Hang
Steroid
Tacrolimus
Idiopathic membranous nephropathy
Decision tree model
Pharmaco
economics
Details
Sugemalimab as first-line treatment for non-small cell lung cancer: a rapid health technology assessment
Published on
Chinese Journal of Pharmacoepidemiology
2025,34(7):806-814.
12899 times
2300 times
HOU Yibing
KANG Shuo
GONG Yuan
WANG Xiaohui
NIE Ying
LIU Huanlong
Sugemalimab
Non-small cell lung cancer
Effectiveness
Safety
Economics
Rapid health technology assessment
Details
Cost-utility analysis of albumin paclitaxel combined with atezolizumab for the treatment of PD-L1-positive advanced triple-negative breast cancer
Published on
Frontiers in Pharmaceutical Sciences
2025,29(7):1179-1185.
12490 times
1861 times
HU Xiuping
TAN Lunan
LI Hongbo
YAO Huitao
Albumin paclitaxel
Atezolizumab
Pharmaco
economics
Cost-utility analysis
Details
Clinical efficacy and pharmacoeconomic evaluation of compound Fengshining tablets in treating knee osteoarthritis
Published on
Chinese Journal of Pharmacoepidemiology
2026,35(1):31-38.
6196 times
1538 times
LU Wencan
YANG Zili
LI Xian
Knee osteoarthritis
Compound Fengshining tablets
Traditional Chinese medicine syndrome
Inflammatory factors
Pharmaco
economics
Details
Rapid health technology assessment of polatuzumab vedotin in the treatment of diffuse large B-cell lymphoma
Published on
Chinese Journal of Pharmacoepidemiology
2026,35(8):922-931.
1198 times
357 times
LIU Xuening
ZHANG Ziye
WANG Kaixuan
ZHAO Zhenying
Polatuzumab vedotin
Diffuse large B-cell lymphoma
Rapid health technology assessment
Safety
Efficacy
Pharmaco
economics
Details
Wuhan University
Zhongnan Hospital of Wuhan University
Center for Evidence-Based and Translational Medicine of Wuhan University